Inhibition of host kinase activity altered by the LMP2A signalosome - A therapeutic target for Epstein-Barr virus latency and associated disease

Antiviral Research

Volumn 56, Issue 3, 2002, Pages 219-231

  Cooper, Lori ^a   Longnecker, Richard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epstein Barr virus (EBV); Phosphatidylinositol 3 kinase; Syk tyrosine kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 DIMETHYLAMINO 1 PHENYL 6 PYRIDAZONE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; INTERLEUKIN 7; LATENT MEMBRANE PROTEIN 2A; LFM A11; LFM A13; METHYLCELLULOSE; PICEATANNOL; PP 3; PROTEIN KINASE BTK; PROTEIN KINASE PI 3KINASE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; IC 50; IN VITRO STUDY; LATENT PERIOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS INFECTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMIDES; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW CELLS; CHROMONES; ENZYME INHIBITORS; ENZYME PRECURSORS; HERPESVIRUS 4, HUMAN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MORPHOLINES; NITRILES; PROTEIN-TYROSINE KINASES; SRC-FAMILY KINASES; STILBENES; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 0036888322     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00110-9     Document Type: Article

References (54)

1. Babcock G.J., Thorley-Lawson D.A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl. Acad. Sci. USA. 97:(22):2000;12250-12255.
2. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity. 9:1998;395-404.
3. Babcock G.J., Decker L.L., Freeman R.B., Thorley-Lawson D.A. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190:(4):1999;567-576.
4. Babcock J.G., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 13:(4):2000;497-506.
5. Braeuninger A., Kuppers R., Strickler J.G., Wacker H.H., Rajewsky K., Hansmann M.L. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc. Natl. Acad. Sci. USA. 94:(17):1997;9337-9342.
6. Burkhardt A.L., Bolen J.B., Kieff E., Longnecker R. An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J. Virol. 66:(8):1992;5161-5167.
7. Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 9:1998;405-411.
8. Caldwell R.G., Brown R.C., Longnecker R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EuLMP2A transgenic mice. J. Virol. 74:2000;1101-1113.
9. Cambier J.C. New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL). Immunol. Today. 16:1995;110.
10. Chen F., Zou J.Z., di Renzo L. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69:1995;3752-3758.
11. Chen H., Smith P., Ambinder R.F., Hayward S.D. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood. 93:(9):1999;3026-3032.
12. Cheng A.M., Rowley B., Pao W., Hayday A., Bolen J.B., Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 378:1995;303-306.
13. Cohen J.I. Epstein-Barr virus infection. New Engl. J. Med. 343:(7):2000;481-492.
14. Engels N., Merchant M., Pappu R., Chan A.C., Longnecker R., Wienands J. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the slp- 65 signaling module. J. Exp. Med. 194:(3):2001;255-264.
15. Era T., Ogawa M., Nishikawa S., Okamoto M., Honjo T., Akagi K., Miyazaki J., Yamamura K. Differentiation of growth signal requirement of B lymphocyte precursor is directed by expression of immunoglobulin. EMBO J. 10:(2):1991;337-342.
16. Fruehling S., Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology. 235:1997;241-251.
17. Fruehling S., Swart R., Dolwick K.M., Kremmer E., Longnecker R. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J. Virol. 72:1998;7796-7806.
18. Geahlen R.L., McLaughlin J.L. Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 165:(1):1989;241-245.
19. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271:(2):1996;695-701.
20. Ikeda T., Kobayashi R., Horiuchi M., Nagata Y., Hasegawa M., Mizuno F., Hirai K. Detection of lymphocytes productively infected with Epstein-Barr virus in non-neoplastic tonsils. J. Gen. Virol. 81 Pt 5:2000;1211-1216.
21. Joseph A.M., Babcock G.J., Thorley-Lawson D.A. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74:(21):2000a;9964-9971.
22. Joseph A.M., Babcock G.J., Thorley-Lawson D.A. EBV persistence involves strict selection of latently infected B cells. J. Immunol. 165:(6):2000b;2975-2981.
23. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med. 184:(4):1996;1495-1505.
24. Kieff E. Fields B.N., Knipe D.M., Howley P.M., Epstein-Barr Virus and Its Replication. Fundamental Virology. 1996;1109-1162 Lippincott-Raven.
25. Kitamura D., Roes J., Kuhn R., Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature. 350:1991;423-426.
26. Kurth J., Spieker T., Wustrow J., Strickler G.J., Hansmann L.M., Rajewsky K., Kuppers R. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 13:(4):2000;485-495.
27. Lam K., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 90:1997;1073-1083.
28. Longnecker R. Molecular biology of Epstein-Barr virus. McCaance D., Human Tumor Viruses. 1998;133-172 American Society for Microbiology.
29. Mahajan S., Ghosh S., Sudbeck E.A., Zheng Y., Downs S., Hupke M., Uckun F.M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide]. J. Biol. Chem. 274:(14):1999;9587-9599.
30. Marafioti T., Hummel M., Foss H.D., Laumen H., Korbjuhn P., Anagnostopoulos I., Lammert H., Demel G., Theil J., Wirth T., Stein H. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 95:(4):2000;1443-1450.
31. Merchant M., Longnecker R. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology. 291:2001;46-54.
32. Merchant M., Caldwell R.G., Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J. Virol. 74:(19):2000;9115-9124.
33. Merchant M., Swart R., Katzman R.B., Ikeda M., Dykstra M.L., Pierce S.K., Longnecker R. The function of LMP2A for the development and activation of B cells. Int. Rev. Immunol. 20:2001;131-161.
34. Miller C.L., Lee J.H., Kieff E., Longnecker R. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl. Acad. Sci. USA. 91:(2):1994;772-776.
35. Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R., Bolen J.B., Kieff E. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 2:1995;155-166.
36. Miyashita E.M., Yang B., Babcock G.J., Thorley-Lawson D.A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71:(7):1997;4882-4891.
37. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaioannou V.E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 68:1992;869-877.
38. Oliver J.M., Burg D.L., Wilson B.S., McLaughlin J.L., Geahlen R.L. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J. Biol. Chem. 269:(47):1994;29697-29703.
39. Peters J.D., Furlong M.T., Asai D.J., Harrison M.L., Geahlen R.L. Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha-tubulin on tyrosine. J. Biol. Chem. 271:(9):1996;4755-4762.
40. Portis T., Cooper L., Dennis P., Longnecker R. The LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. Front Biosci. 7:2002;D414-D426.
41. Qu L., Rowe D. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66:(6):1992;3715-3724.
42. Rickinson A.B., Kieff E. Fields B.N., Knipe D.M., Howley P.M., Epstein-Barr virus, Fields Virology. 1996;2397-2446 Lippincott-Raven Publishers, Philadelphia, PA.
43. Roizman B., Whitley R.J., Lopez C. The Human Herpesviruses. 1994;Raven Press, New York.
44. Scholle F., Bendt K.M., Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74:2000;10681-10689.
45. Shinkai Y., Rathbun G., Lam K., Oltz E.M., Stewart V., Mendelsohn M., Charon J., Datta M., Young F., Stall A.M., Alt F.W. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:1992;855-867.
46. Songyang Z., Shoelson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., King F., Roberts T., Ratnofsky S., Lechleider R.J., et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:(5):1993;767-778.
47. Songyang Z., Shoelson S.E., McGlade J., Olivier P., Pawson T., Bustelo X.R., Barbacid M., Sabe H., Hanafusa H., Yi T., et al. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol. 14:(4):1994;2777-2785.
48. Spanopoulou E., Roman C.A.J., Corcoran L.M., Schlissel M.S., Silver D.P., Nemazee D., Nussenzweig M.C., Shinton S.A., Hardy R.R., Baltimore D. Functional immunogloubulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. Genes Dev. 8:1994;1030-1042.
49. Swart R., Ruf I.K., Sample J., Longnecker R. Latent membrane protein 2A-mediated effects on the Phosphatidylinositol 3-kinase/Akt Pathway. J. Virol. 74:2000;10838-10845.
50. Thorley-Lawson A.D. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:2001;75-82.
51. Tierney R.J., Steven N., Young L.S., Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:(11):1994;7374-7385.
52. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-D]pyrimidines. J. Med. Chem. 40:(22):1997;3601-3616.
53. Turner M., Mee P.J., Costello P.S., Williams O., Price A.A., Duddy L.P., Furlong M.T., Geahlen R.L., Tybulewicz V.L. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 378:(6554):1995;298-302.
54. Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:(7):1994;5241-5248.